Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

Lung Cancer

Volumn 80, Issue 3, 2013, Pages 319-325

  Heigener, David F ^a   von Pawel, Joachim ^b   Eschbach, Corinna ^c   Brune, Andreas ^d   Schmittel, Alexander ^e   Schmelter, Thomas ^d   Reck, Martin ^a   Fischer, Jürgen R ^f  

^a LungenClinic Grosshansdorf   (Germany)

^b ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^c Asklepios Klinik Harburg   (Germany)

^d BAYER PHARMA AG   (Germany)

^e Ärzteforum Seestrasse Medical Center   (Germany)

^f Klinik Lowenstein   (Germany)

Author keywords

Epothilones; Non small cell lung carcinoma; Phase II study; Randomized; Sagopilone; Second line therapy

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; SAGOPILONE; TAXANE DERIVATIVE;

ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEURALGIA; NEUROTOXICITY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOTHIAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPOTHILONES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84877125874     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.02.007     Document Type: Article

References (32)

1. Bareschino M.A., Schettino C., Rossi A., Maione P., Sacco P.C., Zeppa R., et al. Treatment of advanced non small cell lung cancer. J Thorac Dis 2011, 3:122-133.
2. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., et al. Twenty-two years of Phase III trials for patients with advanced non-smallcell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
3. Ihde D.C., Minna J.D. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. Curr Probl Cancer 1991, 15:61-104.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung carcinoma V.3.2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
5. Huizing M.T., Misser V.H., Pieters R.C., ten Bokkel Huinink W.W., Veenhof C.H., Vermorken J.B., et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995, 13:381-404.
6. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
7. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. the TAX 320 non-small cell lung cancer study group. J Clin Oncol 2000, 18:2354-2362.
8. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
9. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
10. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
11. Cheng K.L., Bradley T., Budman D.R. Novel microtubule-targeting agents - the epothilones. Biologics 2008, 2:789-811.
12. Klar U., Hoffmann J., Giurescu M. Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate. Expert Opin Investig Drugs 2008, 17:1735-1748.
13. Hammer S., Fichtner I., Becker M., Sommer A., Klar U., Hoffmann J. Comparative profiling of the novel epothilone ZK-EPO in xenografts derived from primary non-small-cell lung cancer. AACR Meeting Abstracts, 2007 2007, Abstract 3482.
14. Klar U., Buchmann B., Schwede W., Skuballa W., Hoffmann J., Lichtner R.B. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006, 45:7942-7948.
15. Hammer S., Lage H., Eschenbrenner J., Winsel S., Mittelstaedt K., Buchmann B., et al. Promising antitumor activity of the novel epothilone ZK-EPO in multidrug-resistant tumor models. AACR Meeting Abstracts 2007 2007, Abstract 2294.
16. Hoffmann J., Vitale I., Buchmann B., Galluzzi L., Schwede W., Senovilla L., et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008, 68:5301-5308.
17. Arnold D., Voigt W., Kiewe P., Behrmann C., Lindemann S., Reif S., et al. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 2009, 101:1241-1247.
18. Schmid P., Kiewe P., Possinger K., Korfel A., Lindemann S., Giurescu M., et al. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 2010, 21:633-639.
19. Rustin G., Reed N., Jayson G.C., Ledermann J.A., et al. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol. 2011, 22(November (11)):2411-2416.
20. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
21. TNM Classification of malignant tumours 2002, John Wiley & Sons, Hoboken, New Jersey. 6th ed.
22. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
23. Cassidy J., Paul J., Soukop M., Habeshaw T., Reed N.S., Parkin D., et al. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 1998, 41:161-166.
24. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
25. Vansteenkiste J., Lara P.N., Le Chevalier T., Breton J.L., Bonomi P., Sandler A.B., et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007, 25:3448-3455.
26. Beer T., Smith D.C., Hussain A., Alonso M., Neerukonda L., Hauke R., et al. Phase II study of first-line sagopilone combined with prednisone in patients with metastatic androgen-independent prostate cancer (AIPC). Ann Oncol 2008, 19(Suppl. 8). [Abstract 616P].
27. Daud A., Weber J., Urbas P., Andrews S., Maker N., Sondak V.K., et al. Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma. J Clin Oncol (Meeting Abstracts) 2009, 27(Suppl. 15). [Abstract 9031].
28. Rustin G., Reed N., Jayson G.C., Ledermann J.A., Adams M., Perren T., et al. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol 2011, 22:2411-2416.
29. Gatzemeier U., von Pawel J.V., Eschbach C., Brune A., Wagner A., Giurescu M., et al. Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. Eur J Cancer 2007, 5. [Abstract 6568].
30. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
31. Ochs J., Grous J.J., Warner K.L. Final survival and safety results for 21,064 nonsmall- cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP). J Clin Oncol 2004, 22(14S). Abstract7060.
32. West H., Franklin W.A., Gumerlock P.H., Vance R.B., Lau D.H.M., McCoy J., et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. J Clin Oncol 2004, 22(14S). Abstract 7014.